PM
Prosight Management Portfolio holdings
AUM
$580M
Turnover
39.22%
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
+16.3%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$122M
AUM Growth
-$94.3M
(-44%)
Cap. Flow
-$101M
Cap. Flow
% of AUM
-82.94%
Top 10 Holdings %
Top 10 Hldgs %
59.86%
Holding
56
New
14
Increased
5
Reduced
18
Closed
19
Avg Time Held Equity + Options
0.7
years
Top 10 Avg Time Held Equity + Options
0.5
years
Top 20 Avg Time Held Equity + Options
0.8
years
Avg Time Held Equity only
0.7
years
Top 10 Avg Time Held Equity only
0.5
years
Top 20 Avg Time Held Equity only
0.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$6.12M |
| 2 |
Kezar Life Sciences
KZR
|
+$4.39M |
| 3 |
Cellectis
CLLS
|
+$3.41M |
| 4 |
Oscar Health
OSCR
|
+$3.35M |
| 5 |
Solid Biosciences
SLDB
|
+$2.36M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Organogenesis Holdings
ORGO
|
+$27.2M |
| 2 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$25.8M |
| 3 |
Prothena Corp
PRTA
|
+$9.24M |
| 4 |
Baxter International
BAX
|
+$9.15M |
| 5 |
Cigna
CI
|
+$8.62M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.63% |
| 2 | Energy | 1.37% |
| 3 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
PUT
State Street SPDR NYSE Technology ETF
XNTK
$1.99B
| – | – |
-10,000
| Closed | -$1.41M | – |
|
|
RETA
52
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| – | – |
-12,112
| Closed | -$1.5M | – |
|
|
CHNG
53
DELISTED
Change Healthcare Inc. Common Stock
CHNG
| – | – |
-420,514
| Closed | -$7.84M | – |
|
|
ARNA
54
CALL
DELISTED
Arena Pharmaceuticals Inc
ARNA
| – | – |
-18,000
| Closed | -$1.38M | – |
|
|
MGLN
55
DELISTED
Magellan Health Services, Inc.
MGLN
| – | – |
-37,969
| Closed | -$3.15M | – |
|
|
ALXN
56
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
| – | – |
-40,000
| Closed | -$6.25M | – |
|
Similar funds
SC
CCWM
CMA
RIS
MFS
GFI
PWM
CA
Prosight Management's Q1 2021 Portfolio in Review
As of Q1 2021, Prosight Management held 56 positions worth $122M, down 44% from $216M the previous quarter. Its ten largest holdings account for 60% of the portfolio.
Prosight Management withdrew a net $101M in Q1 2021, closing 19 positions and reducing 18 holdings. Its most notable exit was Cigna, an estimated $8.62M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 88% a quarter earlier, followed by Energy and Technology.
Against the trend, Prosight Management opened a new position in Lakefront Biotherapeutics American Depositary Shares worth $5.12M.
- Prosight Management's largest Q1 2021 buy was Lakefront Biotherapeutics American Depositary Shares: 66,419 shares worth $5.12M.
- Prosight Management added most to Vertex Pharmaceuticals in Q1 2021, an estimated $2.08M increase.
- Prosight Management's biggest Q1 2021 reduction was Organogenesis Holdings, cutting an estimated $27.2M.
- Prosight Management fully exited Cigna in Q1 2021, selling an estimated $8.62M.
- Prosight Management's ten largest holdings make up 60% of its $122M portfolio in Q1 2021.
- Prosight Management opened 14 new positions and closed 19 in Q1 2021.
- Prosight Management's portfolio value fell 44% quarter-over-quarter to $122M.
Based on Prosight Management's 13F filing for Q1 2021, filed 14 May 2021.